IRAK1/4 and BET bromodomain inhibitions converge on NF-κB blockade and display synergistic antitumor activity in ABC-DLBCL with MYD88L265P mutation

ABSTRACT: Diffuse large B cell lymphoma cell lines of the activated B cell subtype (ABC-DLBCL) were treated for 6h with IRAK1/4 inhibitor (50µM) followed or not by a 18h exposure to 500 nM CPI203 We used microarrays to uncover the mechanisms underlying IRAKi+BETi activity in ABC-DLBCL

ORGANISM(S): Homo sapiens

PROVIDER: GSE159915 | GEO | 2020/10/24

REPOSITORIES: GEO